Clicking 3′-Azidothymidine into Novel Potent Inhibitors of Human Immunodeficiency Virus

Citations Over TimeTop 10% of 2013 papers

Abstract

3'-Azidothymidine (AZT) was the first approved antiviral for the treatment of human immunodeficiency virus (HIV). Reported efforts in clicking the 3'-azido group of AZT have not yielded 1,2,3-triazoles active against HIV or any other viruses. We report herein the first AZT-derived 1,2,3-triazoles with submicromolar potencies against HIV-1. The observed antiviral activities from the cytopathic effect (CPE) based assay were confirmed through a single replication cycle assay. Structure-activity-relationship (SAR) studies revealed two structural features key to antiviral activity: a bulky aromatic ring and the 1,5-substitution pattern on the triazole. Biochemical analysis of the corresponding triphosphates showed lower ATP-mediated nucleotide excision efficiency compared to AZT, which along with molecular modeling suggests a mechanism of preferred translocation of triazoles into the P-site of HIV reverse transcriptase (RT). This mechanism is corroborated with the observed reduction of fold resistance of the triazole analogue to an AZT-resistant HIV variant (9-fold compared to 56-fold with AZT).

Related Papers

• → Design of Annulated Pyrazoles as Inhibitors of HIV-1 Reverse Transcriptase(2008)74 cited
• → Zidovudine (AZT) Monotherapy Selects for the A360V Mutation in the Connection Domain of HIV-1 Reverse Transcriptase(2012)13 cited
• → Quinoxapeptins: Novel Chromodepsipeptide Inhibitors of HIV-1 and HIV-2 Reverse Transcriptase. I. The Producing Organism and Biological Activity.(1996)52 cited
• → Design, synthesis and biological evaluation of substituted (+)-SG-1 derivatives as novel anti-HIV agents(2018)13 cited
• → Novel Modifications in the Alkenyldiarylmethane (ADAM) Series of Non-Nucleoside Reverse Transcriptase Inhibitors(1999)43 cited